Optical Dosimeter-guided Photodynamic Therapy

光剂量计引导光动力治疗

• 批准号: 9254928
• 负责人: STEVEN J DAVIS
• 金额: $ 22.26万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9254928
• 关键词: Address; Animal Experimentation; Animals; Arts; Cancerous; Cells; Clinic; Clinical; Clinical Research; Coupled; Darkness; Detection; Devices; Discrimination; Dose; Electronics; Environment; Evaluation; Feedback; Fiber; Fluorescence; Funding; Goals; Government; Image; In Vitro; Individual; Kinetics; Lasers; Lead; Light; Measures; Methods; Modality; Modeling; Molecular; Monitor; Mus; Noise; Optics; Oxygen; PUVA Photochemotherapy; Patients; Performance; Persons; Phase; Photons; Photosensitization; Photosensitizing Agents; Phototherapy; Physicians; Physiologic pulse; Process; Research; Research Personnel; Sampling; Signal Transduction; Singlet Oxygen; Site; Small Business Innovation Research Grant; Source; System; Technology; Testing; Time; Tissues; Treatment Efficacy; Treatment outcome; Tube; Tumor Oxygenation; United States National Institutes of Health; Visible Radiation; base; cancer cell; cancer therapy; chemotherapy; clinical application; college; design; design and construction; detector; imaging system; improved; improved outcome; in vivo; individual patient; instrument; killings; light intensity; meetings; phase 1 study; photomultiplier; physical science; predicting response; programs; prototype; response; sensor; tool; treatment response; tumor

Photodynamic Therapy (PDT) is a promising modality for cancer treatment. Oxygen molecules in the metastable singlet delta state O2(1Δ) are believed to be the species that destroys cancerous cells during PDT. Despite the benefit of targeted PDT that kills tumors selectively with minimum effect on surrounding healthy tissues, at the present time it is difficult, if not impossible, to predict the response of an individual to PDT. This has inhibited the acceptance of PDT for clinical uses. Under NCI SBIR funding, Physical Sciences Inc. (PSI) has developed two prototype, in vivo capable dosimeters for PDT: a non-imaging ultra- sensitive photomultiplier tube (PMT)-based point sensor for singlet O2 detection and a 2D imaging sensor for PS fluorescence and singlet O2 detections. These devices use spectral and temporal discrimination methods to optimize sensitivity. The overall goal of our proposed program is to produce an integrated, imaging PDT system that will use real-time feedback to control PDT light dose during the treatment. In Phase I, we will develop and test a newly introduced 2D imaging camera that incorporates gating below a microsecond and a fast framing rate. This will enhance the sensitivity singlet oxygen by at least an order of magnitude. The system will be based upon PSI's current system platform of the 2D imaging system that has demonstrated the ability to observe singlet O2 and PS fluorescence in vivo produced during PDT. The current system uses a near infrared (NIR) sensitive camera for singlet O2 images. However, this camera does not have a fast time-gating capability, and that limits the detection method to only spectral discrimination. The system will be developed and tested on in vitro samples at PSI then transported to Dartmouth College for in vivo testing. The Phase I study result will be utilized to design a Phase II system for both PDT treatments and dosimeters. A fiber-coupled pulsed diode laser will be used for the PDT excitation source. The goal of the Phase I study is to demonstrate the detection sensitivity of the newly introduced 2D camera integrated in the PSI detection system. In Phase II the combined PDT system will be designed, built, and tested for extensive performance verification for in vitro and in vivo studies. An accurate dosimeter to optimize the individual treatment response of PDT is necessary to improve the outcomes of PDT in a clinical environment. A fully developed instrument will be a valuable tool first for PDT researchers and subsequently for clinical PDT uses.

光动力疗法（PDT）是癌症的有希望的方式。 据信，可稳定的单线三角洲状态O2（1δ）是在摧毁癌细胞期间的癌细胞 pdt。 目前，健康的组织，即使不是不可能的，也可以预测对 PDT。 Sciences Inc.（PSI）已开发了两个原型的PDT体内剂量计：一种非成像的超模拟超级 敏感的光电倍增管（PMT）基于单重O2检测的点传感器和2D成像传感器 对于PS荧光和Singlet O2检测。 优化灵敏度的方法。 成像PDT系统将使用实时反馈来控制治疗过程中的PDT光剂量。 在第一阶段，我们将开发和测试 微秒和快速的框架速率。 该系统将基于2D成像系统的当前系统平台 已经证明了在PDT期间产生的体内中的单线O2和PS荧光的能力 当前系统使用近红外（NIR）敏感摄像头用于Singlet O2图像 没有快速的门控能力，这将检测方法仅限于 歧视。 Dartmouth Colege用于体内测试。 对于PDT治疗和剂量计。 兴奋来源。 引入了PSI检测系统中的2D摄像头。 对体外和体内研究的广泛性能验证进行设计，建造和测试 为了改善您的精确剂量表以优化PDT的个体治疗响应是必要的 PDT在临床环境中的结果。 研究人员，随后用于临床PDT使用。